Endotoxemia Clinical Trial
Official title:
Pathophysiology and Clinical Relevance of Endotoxin Tolerance in Humans
A number of diseases lead to a so called systemic inflammatory response syndrome (SIRS).
This excessive response is self-destructive and leads to major complications of the initial
disease: dysfunction of the microcirculation, systemic vasodilation, and increased capillary
leakage and oedema. Animal studies have shown that pre-treatment with endotoxin
(lipopolysaccharide or LPS) suppress the excessive immune response and when rechallenged,
the animal survive a normally lethal dose of endotoxin.
Besides a diminished cytokine response, an increased production of leucocytes in the bone
marrow and an increased phagocytosis after pre-treatment with endotoxin is seen. The
combination of these factors: diminished systemic inflammatory response and increased
cellular immunity makes that endotoxin tolerance is a useful tool for preventing the
complications after an excessive inflammatory response.
Further, the presence of cross-tolerance has also been shown: Endotoxin tolerant mice
survive more after induction of a normally lethal fungal infection. Endotoxin tolerance is
also protective for ischemia/reperfusion injury in kidneys, heart and liver. Little data is
known about endotoxin tolerance in human.
The purpose of this study is to induce a state of tolerance through 2 different
administration schedules and monitor the effect of tolerance on pro- and anti-inflammatory
cytokines, other inflammatory parameters and different proteins involved in the signalling
pathway. The effects of tolerance on vascular reactivity will be determined. Finally, the
effect of tolerance on ischemia-reperfusion injury will be investigated.
See protocol ;
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
| Completed |
NCT02922673 -
The Effects of Acetylsalicylic Acid on Immunoparalysis Following Human Endotoxemia
|
N/A | |
| Completed |
NCT01766414 -
In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II
|
Phase 3 | |
| Completed |
NCT04130321 -
Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans
|
N/A | |
| Completed |
NCT02612480 -
Ticagrelor in Human Endotoxemia Response to Human Endotoxemia
|
N/A | |
| Completed |
NCT01474629 -
Probiotic Sport Study
|
N/A | |
| Recruiting |
NCT06147440 -
Different Dietary Patterns
|
N/A | |
| Recruiting |
NCT03901807 -
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
|
N/A | |
| Completed |
NCT03754504 -
Effects of Cranberry Powder Supplements on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
| Completed |
NCT03800277 -
Effect of Cranberry and Agaves Extract on Microbiota and Intestinal Health
|
N/A | |
| Completed |
NCT00785018 -
In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia
|
N/A | |
| Recruiting |
NCT00413348 -
Type 2 Diabetes and the Effect of Probiotics
|
N/A | |
| Recruiting |
NCT00413465 -
Study of Renal Blood Flow During Human Endotoxemia
|
N/A | |
| Completed |
NCT00412906 -
Study of Gene Activity in Fat and Muscle in Diabetics and Healthy Controls
|
N/A | |
| Completed |
NCT05752968 -
Elevated Levels of Antibodies to Endotoxin Core in Hemodialysis Patients With Peripheral Artery Disease
|
||
| Completed |
NCT01374711 -
The Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human Endotoxemia
|
N/A | |
| Completed |
NCT00916448 -
The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia
|
N/A | |
| Completed |
NCT00332267 -
Cerebral Blood Flow and Metabolism During Hypoxia and Endotoxemia
|
N/A | |
| Completed |
NCT03482284 -
Effect of Monosaccharides on Intestinal Barrier Function
|
N/A | |
| Completed |
NCT03972878 -
Foodprint 1.0: Physiological Acute Responses After Consumption of Confectionary Products
|
N/A |